Overview

Surufatinib DDI With a PPI and a CYP3A Inducer

Status:
Completed

Trial end date:
2021-03-02

Target enrollment:

Participant gender:

Summary

The purpose of this is to evaluate the effect of proton pump inhibitor (rabeprazole) and the effect of a CYP3A inducer (rifampin) on the pharmacokinetics of Surufatinib.

Phase:

Phase 1

Details

Lead Sponsor:

Hutchison Medipharma Limited

Treatments:

Rabeprazole
Rifampin